Partner David Rosen was featured in a Clinical Leader Q&A, “Clinical Trial Deaths — Will Clearer Informed Consent Documents Be Enough?” about issues related to clinical trial consent documents, particularly as they relate to the lawsuit filed against the FDA by the Center for Responsible Science, clinical trial participants and the father of a deceased trial participant.
Rosen answered questions about whether or not the lawsuit will be successful, whether or not the current death rate from clinical trial treatments is concerning and what steps clinical trial stakeholders need to take to improve the informed consent process and make trials safer for patients.
Rosen answered questions about whether or not the lawsuit will be successful, whether or not the current death rate from clinical trial treatments is concerning and what steps clinical trial stakeholders need to take to improve the informed consent process and make trials safer for patients.
People
Related News
April 13, 2026
In the News
Increase in Demand and Firm Growth Led Foley to Large Leaps in Revenue and PEP in a 'Year When It All Came Together'
Foley & Lardner LLP saw double-digit increases and all-time highs across all financial metrics in 2025 as noted in The American Lawyer article, “Foley Grows Revenue by Nearly 14%, PEP by 27%, in a 'Year When It All Came Together'.”
April 10, 2026
In the News
Foley's Texas Media Roundtable Highlighted for Insights on Today's Energy Transformations
Foley & Lardner LLP is featured across media for the firm’s recent roundtable discussion on energy trends related to grid reliability, data centers, and capital investments.
April 10, 2026
In the News
Deanna Reitman and Glenn Reitman Highlighted Across Media for Foley Arrival
Foley & Lardner LLP partners Deanna Reitman and Glenn Reitman attracted widespread media coverage for their recent arrival to the firm’s Houston office.